1. Scrip
  2. >>COVID-19

Synairgen Stock Soars 420% On Promise Of Inhaled COVID-19 Drug

Small Study Excites Investors

 
• By Kevin Grogan

Preliminary results show that hospitalized coronavirus patients who received Synairgen's inhaled interferon beta product had a 79% lower risk of developing severe disease compared with placebo.

Covid19_Hospital_Room
Synairgen Drug Shows Potential For Hospitalized COVID-19 Patients • Source: Shutterstock

Small UK biotech Synairgen plc has announced some big news on its inhaled interferon beta candidate, SNG001, which significantly reduced the risk of severe disease in hospitalized patients with COVID-19, sending the firm's shares through the roof.

Southampton-based Synairgen has unveiled preliminary data from a study that recruited 101 patients from nine specialist hospital sites in the UK from 30 March to 27 May. Patient groups were evenly matched in terms of average age at 56.5 years for placebo and 57

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.